Not yet recruiting NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Safusidenib.
- Who it may be relevant to
- Registry conditions: Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Overview
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Interventions
- Drug Safusidenib
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.
Primary outcome measures
- Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR) [Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months]
Secondary outcome measures (9)
- ORR per modified RANO 2.0 assessed by Investigator [Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months]
- Volumetric Tumor Growth Rate (TGR) by BICR [Time frame: From historical scans through the final scan in the study, approximately 18 months]
- Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator [Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months]
- Time to Next Intervention (TTNI) [Time frame: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months]
- Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator [Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months]
- Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator [Time frame: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months]
- Overall Survival (OS) [Time frame: From the date of first dose of study drug until the date of death, approximately 18 months]
- Safety and tolerability [Time frame: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months]
- Seizure Activity [Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months]
Eligibility criteria
Inclusion criteria
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Exclusion criteria
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07703436 · NUV-218-G209